<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Antifungals, Imidazole: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i293.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i293.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i293.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i288.htm">Antifungals</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i292.htm" title="Previous: Terbinafine">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i298.htm" title="Next: Ketoconazole">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i293">Antifungals, Imidazole</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Antifungals, Imidazole</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i290.htm" name="_290">Amphotericin</a></td><td> imidazoles possibly antagonise effects of amphotericin </td><td>Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</td></tr><tr><td><a href="41001i937.htm" name="_937">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  imidazoles advised by manufacturer of artemether/lumefantrine </b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  imidazoles given with atorvastatin </td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  imidazoles given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i841.htm" name="_841">Mizolastine</a></td><td class="cBV"><b> imidazoles possibly inhibit metabolism of mizolastine (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td>anecdotal reports of contraceptive failure when  imidazoles given with oestrogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  imidazoles given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i824.htm" name="_824">Quetiapine</a></td><td class="cBV"><b> imidazoles possibly increase plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i231.htm" name="_231">Reboxetine</a></td><td class="cBV"><b>avoidance of  imidazoles advised by manufacturer of reboxetine </b></td><td></td></tr><tr><td><a href="41001i791.htm" name="_791">Saquinavir</a></td><td> imidazoles possibly increase plasma concentration of saquinavir </td><td></td></tr><tr><td><a href="41001i730.htm" name="_730">Tacrolimus</a></td><td class="cBV"><b> imidazoles possibly increase plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr></tbody></table><p>Antifungals, Imidazole belongs to <b>Antifungals</b>
          but <b>Antifungals</b>
          has no interactions information.
        </p><p><b>Ketoconazole</b> belongs to
      <b>Antifungals, Imidazole</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


























































































<tr><td><a href="41001i30.htm">Alfuzosin</a></td><td> ketoconazole possibly increases plasma concentration of alfuzosin </td><td></td></tr><tr><td><a href="41001i1099.htm">Aliskiren</a></td><td> ketoconazole increases plasma concentration of aliskiren </td><td></td></tr><tr><td><a href="41001i1124.htm">Alitretinoin</a></td><td> ketoconazole increases plasma concentration of alitretinoin </td><td></td></tr><tr><td><a href="41001i925.htm">Almotriptan</a></td><td> ketoconazole increases plasma concentration of almotriptan (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i406.htm">Alprazolam</a></td><td> ketoconazole increases plasma concentration of alprazolam </td><td></td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  ketoconazole reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i342.htm">Antimuscarinics</a></td><td>absorption of  ketoconazole reduced by antimuscarinics </td><td>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</td></tr><tr><td><a href="41001i1217.htm">Apixaban</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of apixaban—manufacturer of apixaban advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1010.htm">Aprepitant</a></td><td> ketoconazole increases plasma concentration of aprepitant </td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> ketoconazole inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of boceprevir </b></td><td></td></tr><tr><td><a href="41001i1116.htm">Bortezomib</a></td><td> ketoconazole increases plasma concentration of bortezomib </td><td></td></tr><tr><td><a href="41001i943.htm">Bosentan</a></td><td> ketoconazole increases plasma concentration of bosentan </td><td></td></tr><tr><td><a href="41001i496.htm">Budesonide</a></td><td> ketoconazole increases plasma concentration of <i>inhaled</i> and <i>oral</i> budesonide </td><td></td></tr><tr><td><a href="41001i87.htm">Buprenorphine</a></td><td class="cBV"><b> ketoconazole inhibits metabolism of buprenorphine (reduce dose of buprenorphine)</b></td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  ketoconazole advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i469.htm">Calcium-channel Blockers (dihydropyridines)</a></td><td> ketoconazole possibly inhibits metabolism of dihydropyridines (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td> ketoconazole possibly increases plasma concentration of carbamazepine </td><td></td></tr><tr><td><a href="41001i1043.htm">Ciclesonide</a></td><td> ketoconazole increases plasma concentration of active metabolite of ciclesonide </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> ketoconazole inhibits metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i940.htm">Cilostazol</a></td><td> ketoconazole increases plasma concentration of cilostazol (consider reducing dose of cilostazol)</td><td></td></tr><tr><td><a href="41001i1022.htm">Cinacalcet</a></td><td> ketoconazole inhibits metabolism of cinacalcet (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> ketoconazole possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b> ketoconazole possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i484.htm">Corticosteroids</a></td><td> ketoconazole possibly inhibits metabolism of corticosteroids </td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> ketoconazole enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1120.htm">Dabigatran Etexilate</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of dabigatran etexilate—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1076.htm">Darifenacin</a></td><td> ketoconazole increases plasma concentration of darifenacin—avoid concomitant use</td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td>plasma concentration of both drugs increased when  ketoconazole given with darunavir </td><td></td></tr><tr><td><a href="41001i1077.htm">Dasatinib</a></td><td> ketoconazole possibly increases plasma concentration of dasatinib </td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  ketoconazole given with disopyramide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i516.htm">Docetaxel</a></td><td><i>in vitro</i> studies suggest a possible interaction between  ketoconazole and docetaxel (consult docetaxel product literature)</td><td></td></tr><tr><td><a href="41001i553.htm">Domperidone</a></td><td class="cBV"><b>manufacturer of  ketoconazole advises avoid concomitant use with domperidone (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of dronedarone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i963.htm">Eletriptan</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of eletriptan (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of eplerenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1048.htm">Erlotinib</a></td><td> ketoconazole inhibits metabolism of erlotinib (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of everolimus—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i471.htm">Felodipine</a></td><td class="cBV"><b> ketoconazole inhibits metabolism of felodipine (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i1119.htm">Fesoterodine</a></td><td>manufacturer of fesoterodine advises dose reduction when  ketoconazole given with fesoterodine—consult fesoterodine product literature</td><td></td></tr><tr><td><a href="41001i1202.htm">Fingolimod</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of fingolimod </b></td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td>plasma concentration of  ketoconazole increased by fosamprenavir (also plasma concentration of fosamprenavir possibly increased)</td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i915.htm">Galantamine</a></td><td> ketoconazole increases plasma concentration of galantamine </td><td></td></tr><tr><td><a href="41001i743.htm">Histamine H<sub>2</sub>-antagonists</a></td><td>absorption of  ketoconazole reduced by histamine H<sub>2</sub>-antagonists </td><td></td></tr><tr><td><a href="41001i933.htm">Imatinib</a></td><td> ketoconazole increases plasma concentration of imatinib </td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of indinavir (consider reducing dose of indinavir)</b></td><td></td></tr><tr><td><a href="41001i1006.htm">Irinotecan</a></td><td class="cBV"><b> ketoconazole reduces plasma concentration of  irinotecan (but concentration of active metabolite of irinotecan increased)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i165.htm">Isoniazid</a></td><td>plasma concentration of  ketoconazole possibly reduced by isoniazid </td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of ivabradine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1092.htm">Lanthanum</a></td><td>absorption of   ketoconazole possibly reduced by lanthanum (give at least 2 hours apart)</td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of lapatinib—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i846.htm">Lercanidipine</a></td><td>avoidance of  ketoconazole advised by manufacturer of lercanidipine </td><td></td></tr><tr><td><a href="41001i309.htm">Loratadine</a></td><td>manufacturer of loratadine advises  ketoconazole possibly increases plasma concentration of loratadine </td><td></td></tr><tr><td><a href="41001i1107.htm">Maraviroc</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of maraviroc (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i337.htm">Mefloquine</a></td><td> ketoconazole increases plasma concentration of mefloquine </td><td></td></tr><tr><td><a href="41001i492.htm">Methylprednisolone</a></td><td> ketoconazole inhibits the metabolism of methylprednisolone </td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of midazolam (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i823.htm">Mirtazapine</a></td><td> ketoconazole increases plasma concentration of mirtazapine </td><td></td></tr><tr><td><a href="41001i841.htm">Mizolastine</a></td><td class="cBV"><b> ketoconazole inhibits metabolism of mizolastine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i968.htm">Mometasone</a></td><td> ketoconazole increases plasma concentration of <i>inhaled</i> mometasone </td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td class="cBV"><b>plasma concentration of  ketoconazole reduced by nevirapine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1118.htm">Nilotinib</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of nilotinib—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1093.htm">Paricalcitol</a></td><td> ketoconazole possibly increases plasma concentration of paricalcitol </td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td class="cBV"><b>avoidance of  ketoconazole advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>plasma concentration of  ketoconazole reduced by phenytoin </b></td><td></td></tr><tr><td><a href="41001i751.htm">Proton Pump Inhibitors</a></td><td>absorption of  ketoconazole reduced by proton pump inhibitors </td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of ranolazine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>metabolism of  ketoconazole accelerated by rifampicin (reduced plasma concentration), also plasma concentration of rifampicin may be reduced by ketoconazole</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>combination of  ketoconazole with ritonavir may increase plasma concentration of either drug (or both)</b></td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of rivaroxaban—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1155.htm">Rupatadine</a></td><td> ketoconazole increases plasma concentration of rupatadine </td><td></td></tr><tr><td><a href="41001i727.htm">Salmeterol</a></td><td> ketoconazole inhibits metabolism of salmeterol (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td> ketoconazole increases plasma concentration of saquinavir </td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td> ketoconazole increases plasma concentration of sildenafil—reduce initial dose of sildenafil</td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  ketoconazole given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of sirolimus—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1020.htm">Solifenacin</a></td><td> ketoconazole increases plasma concentration of solifenacin </td><td></td></tr><tr><td><a href="41001i755.htm">Sucralfate</a></td><td>absorption of  ketoconazole reduced by sucralfate </td><td></td></tr><tr><td><a href="41001i1075.htm">Sunitinib</a></td><td> ketoconazole inhibits metabolism of sunitinib (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of tacrolimus (consider reducing dose of tacrolimus)</b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of tadalafil—manufacturer of tadalafil advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of both drugs possibly increased when  ketoconazole given with telaprevir (increased risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>avoidance of concomitant  ketoconazole in severe renal and hepatic impairment advised by manufacturer of telithromycin </b></td><td></td></tr><tr><td><a href="41001i1137.htm">Temsirolimus</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of active metabolite of temsirolimus—avoid concomitant use</b></td><td>The main active metabolite of temsirolimus is sirolimus—<i>see also</i> interactions of sirolimus and consult product literature</td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td class="cBV"><b> ketoconazole possibly increases plasma concentration of theophylline </b></td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of ticagrelor—manufacturer of ticagrelor advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td>avoidance of  ketoconazole advised by manufacturer of tolterodine </td><td></td></tr><tr><td><a href="41001i1158.htm">Tolvaptan</a></td><td> ketoconazole increases plasma concentration of tolvaptan </td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of vardenafil—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1181.htm">Vinflunine</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of vinflunine—manufacturer of vinflunine advises avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Miconazole</b> belongs to
      <b>Antifungals, Imidazole</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>









<tr><td><a href="41001i277.htm">Carbamazepine</a></td><td> miconazole possibly increases plasma concentration of carbamazepine </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> miconazole possibly inhibits metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> miconazole enhances anticoagulant effect of coumarins (miconazole oral gel and possibly vaginal and topical formulations absorbed)</b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i271.htm">Gliclazide</a></td><td class="cBV"><b> miconazole enhances hypoglycaemic effect of gliclazide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i272.htm">Glipizide</a></td><td class="cBV"><b> miconazole enhances hypoglycaemic effect of glipizide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> miconazole enhances anticonvulsant effect of phenytoin (plasma concentration of phenytoin increased)</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  miconazole given with simvastatin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b> miconazole increases plasma concentration of sirolimus </b></td><td></td></tr><tr><td><a href="41001i268.htm">Sulfonylureas</a></td><td class="cBV"><b> miconazole increases plasma concentration of sulfonylureas </b></td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i298.htm" title="Ketoconazole">Ketoconazole</a></li><li><a href="41001i299.htm" title="Miconazole">Miconazole</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i292.htm">Previous: Terbinafine</a> | <a class="top" href="41001i293.htm#">Top</a> | <a accesskey="]" href="41001i298.htm">Next: Ketoconazole</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>